NASDAQ:LYRA Lyra Therapeutics (LYRA) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Buy LYRA with Qtrade Free LYRA Stock Alerts $0.38 +0.02 (+5.51%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.4250-Day Range$0.36▼$6.5352-Week Range$0.35▼$6.79Volume5.86 million shsAverage Volume8.02 million shsMarket Capitalization$23.35 millionP/E RatioN/ADividend YieldN/APrice Target$7.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Lyra Therapeutics alerts: Email Address Lyra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,760.3% Upside$7.13 Price TargetShort InterestHealthy0.68% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.23Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.18) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.39 out of 5 starsMedical Sector307th out of 921 stocksSurgical & Medical Instruments Industry42nd out of 96 stocks 4.0 Analyst's Opinion Consensus RatingLyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageLyra Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lyra Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.68% of the outstanding shares of Lyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently increased by 24.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyra Therapeutics does not currently pay a dividend.Dividend GrowthLyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYRA. Previous Next 2.1 News and Social Media Coverage News SentimentLyra Therapeutics has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lyra Therapeutics this week, compared to 1 article on an average week.Search Interest23 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 35% compared to the previous 30 days.MarketBeat Follows8 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.42% of the stock of Lyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyra Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lyra Therapeutics are expected to grow in the coming year, from ($1.18) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyra Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyra Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyra Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lyra Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About Lyra Therapeutics Stock (NASDAQ:LYRA)Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Read More LYRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYRA Stock News HeadlinesMay 15, 2024 | finance.yahoo.comTarget upgraded, CVS downgraded: Wall Street's top analyst callsMay 12, 2024 | americanbankingnews.comLyra Therapeutics, Inc. (NASDAQ:LYRA) Expected to Earn FY2027 Earnings of ($0.95) Per ShareMay 10, 2024 | americanbankingnews.comBrokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $7.13May 7, 2024 | markets.businessinsider.comHold Rating on Lyra Therapeutics Amid Clinical Trial Setbacks and Financial UncertaintiesMay 7, 2024 | msn.comBTIG Downgrades Lyra Therapeutics (LYRA)May 7, 2024 | markets.businessinsider.comWhere Lyra Therapeutics Stands With AnalystsMay 6, 2024 | msn.comWhy Lyra Therapeutics Stock Is Down 93% TodayMay 6, 2024 | markets.businessinsider.comLyra Therapeutics's Phase 3 Enlighten Trial 1 Fails To Meet Primary Endpoint; Stock DownMay 6, 2024 | marketwatch.comLyra Therapeutics Shares Plummet 90% After Chronic Rhinosinusitis Drug Fails in StudyMay 6, 2024 | investorplace.comWhy Is Lyra Therapeutics (LYRA) Stock Down 90% Today?May 6, 2024 | marketwatch.comLyra Therapeutics Lead Drug Candidate Fails in Phase 3 StudyMay 6, 2024 | globenewswire.comLyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lyra Therapeutics Amid Strong Phase 3 Prospects for LYR-210May 2, 2024 | finance.yahoo.comLyra Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lyra Therapeutics Amid Favorable LYR-210 Trial Outcomes and Strategic CRS Market PositioningMay 1, 2024 | markets.businessinsider.comBuy Rating for Lyra Therapeutics Backed by Upcoming Catalysts and Market PotentialApril 30, 2024 | globenewswire.comLyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 26, 2024 | globenewswire.comLyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 26, 2024 | newsweek.comWorld's Best Digital Health Companies 2024 - TreatmentMarch 26, 2024 | finance.yahoo.comPrivate equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as wellMarch 23, 2024 | finance.yahoo.comLyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS ProjectionsMarch 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lyra Therapeutics’ LYR-210 Amidst Phase 3 Trial and Market OpportunityMarch 22, 2024 | msn.comLyra Therapeutics files for $300M mixed shelfMarch 21, 2024 | globenewswire.comLyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 15, 2024 | finance.yahoo.comLYRA Jul 2024 2.500 callSee More Headlines Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today5/18/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LYRA CUSIPN/A CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees88Year FoundedN/APrice Target and Rating Average Stock Price Target$7.13 High Stock Price Target$15.00 Low Stock Price Target$0.50 Potential Upside/Downside+1,760.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,680,000.00 Net Margins-4,099.82% Pretax Margin-4,096.31% Return on Equity-77.34% Return on Assets-51.00% Debt Debt-to-Equity RatioN/A Current Ratio4.78 Quick Ratio4.78 Sales & Book Value Annual Sales$1.56 million Price / Sales14.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book0.30Miscellaneous Outstanding Shares60,970,000Free Float50,345,000Market Cap$23.35 million OptionableOptionable Beta0.31 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Harlan W. Waksal M.D. (Age 71)Executive Chairman Comp: $210.06kDr. Maria Palasis Ph.D. (Age 59)CEO, President & Director Comp: $942.7kDr. John E. Bishop Ph.D. (Age 62)Chief Technology Officer Comp: $662.9kDr. Carmichael S. Roberts Jr. (Age 55)Ph.D., Co-Founder Mr. Jason Cavalier (Age 51)CFO, Treasurer & Secretary Comp: $464.11kMr. Ray KnoxVice President of OperationsMs. Ellen CavaleriSenior Vice President of Investor Relations & CommunicationsMr. Ronan P. O'Brien J.D. (Age 51)Chief Legal Officer Ms. Corinne Noyes (Age 56)Senior Vice President of Commercial Strategy & Market Development Comp: $426.73kMs. Vineeta Belanger Ph.D.Senior Vice President of Clinical AffairsMore ExecutivesKey CompetitorsPolyPidNASDAQ:PYPDNephrosNASDAQ:NEPHT2 BiosystemsNASDAQ:TTOOPAVmedNASDAQ:PAVMMeihua International Medical TechnologiesNASDAQ:MHUAView All CompetitorsInsiders & InstitutionsIkarian Capital LLCSold 197,555 shares on 5/17/2024Ownership: 1.733%Vanguard Group Inc.Bought 410,021 shares on 5/10/2024Ownership: 2.430%Rosalind Advisors Inc.Sold 744,196 shares on 4/25/2024Ownership: 1.916%Harlan WaksalBought 25,000 shares on 11/10/2023Total: $74,000.00 ($2.96/share)Perceptive Advisors LlcBought 3,610,832 shares on 5/31/2023Total: $8.99 M ($2.49/share)View All Insider TransactionsView All Institutional Transactions LYRA Stock Analysis - Frequently Asked Questions Should I buy or sell Lyra Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LYRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYRA, but not buy additional shares or sell existing shares. View LYRA analyst ratings or view top-rated stocks. What is Lyra Therapeutics' stock price target for 2024? 6 analysts have issued 1-year price objectives for Lyra Therapeutics' shares. Their LYRA share price targets range from $0.50 to $15.00. On average, they expect the company's share price to reach $7.13 in the next twelve months. This suggests a possible upside of 1,760.3% from the stock's current price. View analysts price targets for LYRA or view top-rated stocks among Wall Street analysts. How have LYRA shares performed in 2024? Lyra Therapeutics' stock was trading at $5.24 at the beginning of the year. Since then, LYRA shares have decreased by 92.7% and is now trading at $0.3830. View the best growth stocks for 2024 here. When is Lyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our LYRA earnings forecast. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (NASDAQ:LYRA) issued its earnings results on Tuesday, April, 30th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.09. The firm had revenue of $0.53 million for the quarter, compared to the consensus estimate of $0.40 million. Lyra Therapeutics had a negative net margin of 4,099.82% and a negative trailing twelve-month return on equity of 77.34%. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE). When did Lyra Therapeutics IPO? Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager. Who are Lyra Therapeutics' major shareholders? Lyra Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.43%), Rosalind Advisors Inc. (1.92%) and Ikarian Capital LLC (1.73%). Insiders that own company stock include C Ann Merrifield, Edward T Anderson, Harlan Waksal, Mukesh Mehta, Nbvm Gp, Llc and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LYRA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.